|
WO2009091531A2
(en)
*
|
2008-01-16 |
2009-07-23 |
The General Hospital Corporation |
Uniform-sized, multi-drug carrying and photosensitive liposomes for advance drug delivery
|
|
ES2584381T3
(es)
|
2010-05-05 |
2016-09-27 |
Prolynx Llc |
Liberación controlada de compuestos activos desde conjugados macromoleculares
|
|
BR112013031556B1
(pt)
|
2011-06-06 |
2022-03-29 |
Starpharma Pty Ltd |
Macromoléculas, uso das mesmas para tratar ou suprimir o crescimento de um câncer e composições farmacêuticas
|
|
JP6158185B2
(ja)
|
2011-09-07 |
2017-07-05 |
プロリンクス エルエルシー |
生分解性架橋を有するヒドロゲル
|
|
WO2013036857A1
(en)
*
|
2011-09-07 |
2013-03-14 |
Prolynx Llc |
Sulfone linkers
|
|
JP6290187B2
(ja)
*
|
2012-05-11 |
2018-03-07 |
クランツ，アレクサンダー |
癌の処置のためのタンパク質の部位特異的標識及び標的送達
|
|
EP2925256A4
(en)
*
|
2013-01-22 |
2016-08-17 |
Prolynx Llc |
SEALANTS HAVING CONTROLLED DEGRADATION
|
|
WO2014205126A1
(en)
|
2013-06-19 |
2014-12-24 |
The Regents Of The University Of California |
Chemical structures for localized delivery of therapeutic agents
|
|
SG11201603115YA
(en)
*
|
2013-10-22 |
2016-05-30 |
Prolynx Llc |
Conjugates of somatostatin and its analogs
|
|
WO2015095755A1
(en)
*
|
2013-12-19 |
2015-06-25 |
Seattle Genetics, Inc. |
Methylene carbamate linkers for use with targeted-drug conjugates
|
|
CN106659796B
(zh)
|
2014-03-14 |
2021-04-30 |
加利福尼亚大学董事会 |
Tco缀合物和治疗剂递送方法
|
|
CA3008017C
(en)
|
2016-01-08 |
2024-01-02 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release cnp agonists with reduced side-effects
|
|
US10835578B2
(en)
|
2016-01-08 |
2020-11-17 |
Ascendis Pharma Growth Disorders A/S |
CNP prodrugs with large carrier moieties
|
|
AU2017205688C1
(en)
|
2016-01-08 |
2022-03-10 |
Ascendis Pharma Growth Disorders A/S |
Cnp prodrugs with carrier attachment at the ring moiety
|
|
AU2017205690B2
(en)
|
2016-01-08 |
2022-04-28 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release CNP agonists with increased NEP stability
|
|
NZ743488A
(en)
|
2016-01-08 |
2023-02-24 |
Ascendis Pharma Growth Disorders As |
Controlled-release cnp agonists with low initial npr-b activity
|
|
AU2017205694B2
(en)
|
2016-01-08 |
2022-05-26 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release CNP agonists with low NPR-C binding
|
|
IL317744A
(en)
*
|
2016-03-01 |
2025-02-01 |
Ascendis Pharma Bone Diseases As |
PTH drug agonists
|
|
JP7017248B2
(ja)
*
|
2016-03-16 |
2022-02-08 |
プロリンクス エルエルシー |
エキセナチド類似体の持続放出コンジュゲート
|
|
EP3484523A1
(en)
|
2016-07-13 |
2019-05-22 |
Ascendis Pharma A/S |
Conjugation method for carrier-linked prodrugs
|
|
PL3518961T3
(pl)
|
2016-09-29 |
2023-08-14 |
Ascendis Pharma Bone Diseases A/S |
Związki pth o niskim stosunku wartości maksymalnej do minimalnej
|
|
RS64440B1
(sr)
|
2016-09-29 |
2023-09-29 |
Ascendis Pharma Bone Diseases As |
Režim doziranja za pth jedinjenje sa kontrolisanim oslobađanjem
|
|
FI3518982T3
(fi)
|
2016-09-29 |
2025-02-11 |
Ascendis Pharma Bone Diseases As |
Säädellysti vapautuvia PTH-yhdisteitä
|
|
HRP20230385T1
(hr)
|
2016-09-29 |
2023-06-23 |
Ascendis Pharma Growth Disorders A/S |
Kombinirana terapija sa cnp agonistima s kontroliranim oslobađanjem
|
|
TWI773730B
(zh)
|
2017-02-22 |
2022-08-11 |
瑞典商阿斯特捷利康公司 |
治療性樹枝狀聚合物
|
|
IL269506B2
(en)
|
2017-03-22 |
2024-04-01 |
Genentech Inc |
Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
|
|
JOP20190245A1
(ar)
|
2017-04-20 |
2019-10-15 |
Novartis Ag |
أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
|
|
EP3684785B1
(en)
|
2017-09-19 |
2024-10-02 |
Technische Universität München |
N-methylated cyclic peptides and their prodrugs
|
|
EP3684417A1
(en)
*
|
2017-09-19 |
2020-07-29 |
Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. |
Lipophilic peptide prodrugs
|
|
EP3737383A4
(en)
|
2018-01-12 |
2021-12-15 |
Prolynx LLC |
SYNERGISTIC CANCER TREATMENT
|
|
WO2019177740A1
(en)
*
|
2018-03-12 |
2019-09-19 |
Boston Scientific Scimed, Inc. |
Scavenging methods, and scavenging system for radiocontrast agents
|
|
CA3093083A1
(en)
|
2018-03-28 |
2019-10-03 |
Ascendis Pharma A/S |
Conjugates
|
|
CN119504973A
(zh)
|
2018-03-28 |
2025-02-25 |
阿森迪斯药物肿瘤股份有限公司 |
Il-2缀合物
|
|
CA3099620A1
(en)
|
2018-05-18 |
2019-11-21 |
Ascendis Pharma Bone Diseases A/S |
Starting dose of pth conjugates
|
|
US12071517B2
(en)
|
2018-07-19 |
2024-08-27 |
Starpharma Pty Ltd. |
Therapeutic dendrimer
|
|
CA3106568A1
(en)
|
2018-07-19 |
2020-01-23 |
Starpharma Pty Ltd |
Therapeutic dendrimer
|
|
EP3856255A1
(en)
|
2018-09-26 |
2021-08-04 |
Ascendis Pharma A/S |
Treatment of infections
|
|
MX2021003186A
(es)
|
2018-09-26 |
2021-07-16 |
Ascendis Pharma As |
Nuevos conjugados de hidrogel.
|
|
US12594345B2
(en)
|
2018-09-26 |
2026-04-07 |
Ascendis Pharma A/S |
Degradable hyaluronic acid hydrogels
|
|
AR116566A1
(es)
|
2018-10-03 |
2021-05-19 |
Novartis Ag |
Administración sostenida de polipéptidos similares a la angiopoyetina 3
|
|
WO2020141223A1
(en)
|
2019-01-04 |
2020-07-09 |
Ascendis Pharma A/S |
Induction of sustained local inflammation
|
|
SG11202105833WA
(en)
|
2019-01-04 |
2021-07-29 |
Ascendis Pharma Oncology Div A/S |
Minimization of systemic inflammation
|
|
US20220054476A1
(en)
|
2019-01-04 |
2022-02-24 |
Ascendis Pharma Oncology Division A/S |
Sustained local drug levels for innate immune agonists
|
|
TWI856997B
(zh)
|
2019-01-04 |
2024-10-01 |
丹麥商阿仙帝斯製藥公司 |
模式辨別受體(pattern recognition receptor)促效劑的共軛物
|
|
EP3923906A1
(en)
|
2019-02-11 |
2021-12-22 |
Ascendis Pharma Growth Disorders A/S |
Dry pharmaceutical formulations of cnp conjugates
|
|
US12403182B2
(en)
|
2019-02-11 |
2025-09-02 |
Ascendis Pharma Bone Diseases A/S |
Liquid pharmaceutical formulations of PTH conjugates
|
|
CN114286693A
(zh)
*
|
2019-04-05 |
2022-04-05 |
普罗林科斯有限责任公司 |
改良偶联接头
|
|
SG11202111175YA
(en)
*
|
2019-04-26 |
2021-11-29 |
Prolynx Llc |
Slow-release cytokine conjugates
|
|
WO2020247151A1
(en)
|
2019-06-05 |
2020-12-10 |
Boston Scientific Scimed, Inc. |
Click chemistry capturable platinum-based antineoplastic agents
|
|
WO2020254617A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Anti-ctla4 compounds with localized pk properties
|
|
WO2020254613A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Controlled-release tyrosine kinase inhibitor compounds with localized pk properties
|
|
CA3143278A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Tyrosine kinase inhibitor conjugates
|
|
AU2020295721B2
(en)
*
|
2019-06-21 |
2025-04-03 |
Ascendis Pharma A/S |
Conjugates of π-electron-pair-donating heteroaromatic nitrogen-comprising compounds
|
|
TW202114738A
(zh)
|
2019-06-21 |
2021-04-16 |
丹麥商阿仙帝斯製藥公司 |
抗ctla4結合物
|
|
WO2020254607A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Anti-ctla4 compounds with localized pd properties
|
|
WO2020254612A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Controlled-release tyrosine kinase inhibitor compounds with localized pd properties
|
|
CN114630818A
(zh)
*
|
2019-09-30 |
2022-06-14 |
北京轩义医药科技有限公司 |
蛋白-大分子偶联物及其使用方法
|
|
CN115003320A
(zh)
|
2020-01-13 |
2022-09-02 |
阿森迪斯药物骨疾病股份有限公司 |
甲状旁腺功能减退的治疗
|
|
AU2021269007A1
(en)
|
2020-05-04 |
2022-11-24 |
Ascendis Pharma A/S |
Hydrogel irradiation
|
|
IL298642A
(en)
|
2020-06-03 |
2023-01-01 |
Ascendis Pharma Oncology Div A/S |
il-2 sequences and uses thereof
|
|
CA3189715A1
(en)
|
2020-08-28 |
2022-03-03 |
Ascendis Pharma Oncology Division A/S |
Glycosylated il-2 proteins and uses thereof
|
|
EP4217004A1
(en)
|
2020-09-28 |
2023-08-02 |
Ascendis Pharma Bone Diseases A/S |
Improvement of physical and mental well-being of patients with hypoparathyroidism
|
|
KR20230164709A
(ko)
|
2021-04-01 |
2023-12-04 |
아센디스 파마 에이에스 |
염증 유발 질환을 치료하기 위한 지속형 성장 호르몬의 용도
|
|
EP4404951A1
(en)
|
2021-09-22 |
2024-07-31 |
Ascendis Pharma Bone Diseases A/S |
Long-acting pth compound treatments
|
|
WO2023069510A1
(en)
*
|
2021-10-19 |
2023-04-27 |
The United States Government As Represented By The Department Of Veterans Affairs |
Cannabinoid compositions for gastroesophageal disorders
|
|
CA3236278A1
(en)
|
2021-12-13 |
2023-06-22 |
Kennett Sprogoe |
Effective doses of cnp conjugates
|
|
MX2024006698A
(es)
|
2021-12-13 |
2024-06-19 |
Ascendis Pharma Oncology Div A/S |
Tratamientos de cancer con agonistas de los receptores tipo toll 7 y 8 (tlr7/8).
|
|
WO2023227505A1
(en)
|
2022-05-23 |
2023-11-30 |
Ascendis Pharma Growth Disorders A/S |
Liquid pharmaceutical formulations of cnp compounds
|
|
CN114874624B
(zh)
*
|
2022-05-27 |
2023-04-07 |
深圳市博致远科技有限公司 |
一种导热吸波室温固化硅橡胶产品及其制备方法
|
|
CN120752051A
(zh)
|
2022-11-02 |
2025-10-03 |
阿森迪斯药物骨疾病股份有限公司 |
包含两种pth化合物的pth治疗方案
|
|
WO2024104922A1
(en)
|
2022-11-14 |
2024-05-23 |
Ascendis Pharma Growth Disorders A/S |
Method of improving skeletal muscle function
|
|
TW202430223A
(zh)
|
2023-01-05 |
2024-08-01 |
丹麥商阿仙帝斯眼科製藥有限公司 |
用於治療眼部病症之藥物結合物
|
|
TW202434299A
(zh)
|
2023-01-05 |
2024-09-01 |
丹麥商阿仙帝斯製藥公司 |
製造水凝膠微球之方法
|
|
AU2024232125A1
(en)
|
2023-03-06 |
2025-08-28 |
Ascendis Pharma A/S |
Compounds of drugs with an albumin binding moiety
|
|
AU2024233842A1
(en)
|
2023-03-06 |
2025-09-04 |
Ascendis Pharma A/S |
Multi-albumin binding compounds
|
|
IL323039A
(en)
|
2023-03-06 |
2025-10-01 |
Ascendis Pharma As |
Drug compounds containing albumin-binding moieties
|
|
JP2026510974A
(ja)
|
2023-03-20 |
2026-04-10 |
アセンディス ファーマ グロース ディスオーダーズ エー／エス |
軟骨形成不全症のヒト対象における胸腰椎奇形の治療の方法
|
|
WO2024231442A1
(en)
|
2023-05-09 |
2024-11-14 |
Ascendis Pharma Oncology Division A/S |
Novel cancer treatments with il-2 conjugates
|
|
IL326658A
(en)
|
2023-09-04 |
2026-04-01 |
Ascendis Pharma Bone Diseases As |
PTH treatment in chronic kidney disease
|
|
WO2025208117A1
(en)
*
|
2024-03-29 |
2025-10-02 |
Maha Therapeutics, Inc. |
Cleavable ester compounds and uses thereof
|
|
WO2026013135A1
(en)
|
2024-07-10 |
2026-01-15 |
Ascendis Pharma A/S |
Albumin-binding reagents
|
|
WO2026013136A1
(en)
|
2024-07-10 |
2026-01-15 |
Ascendis Pharma A/S |
Albumin-binding compounds
|
|
WO2026013138A1
(en)
|
2024-07-10 |
2026-01-15 |
Ascendis Pharma A/S |
Compounds with improved albumin-binding
|